Media Release

14 April 2005

Annual General Meeting of the Shareholders in Basel, Switzerland

ALLSCHWIL/BASEL, SWITZERLAND – 14 April 2005 – At today's Annual General Meeting of Actelion Ltd (SWX: ATLN), shareholders approved the following resolutions:

- Increase of the conditional capital by CHF 2.5 million (1 million shares), reserved for the issuance of employee stock options

- Extension of the period for the Authorized Capital, which was increased to CHF 27.5 million (11 million shares), until 14 April 2007

The shareholders also approved the annual report, including the financial statements, for the year 2004. They also elected Juhani Anttila and Carl Feldbaum to serve on the Actelion Board of Directors. The shareholders also confirmed Rob Cawthorn and Dr. Jean-Paul Clozel as members of the board for another three years.

Following the departure of former board member Fred Meyer per year end 2004, the board of directors is now composed of 8 members: Robert E. Cawthorn (Chairman), André J. Mueller (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Armin Kessler, Jean Malo, Juhani Anttila and Carl Feldbaum.

The Annual General Meeting of Actelion took place in Basel. It was attended by 179 shareholders, representing 10’262’481 shares or 46.11 percent of the total outstanding shares.

###

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarter in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union as well as Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact:

Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil

Investor Contact	Roland Haefeli	+41 61 565 64 58 +1 650 624 6936
Media Contact	Peter Engel	+41 61 565 66 28

http:// www.actelion.com